These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17906340)

  • 21. The use of drug-eluting stents in venous coronary artery bypass grafts.
    Hernandez-Antolín R; Alfonso F; Jimenez P
    EuroIntervention; 2009 May; 5 Suppl D():D51-7. PubMed ID: 19736072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era.
    Meliga E; García-García HM; Kukreja N; Daemen J; Tanimoto S; Ramcharitar S; van Mieghem CA; Sianos G; van der Ent M; van der Giessen WJ; de Feyter P; van Domburg R; Serruys PW
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):21-5. PubMed ID: 17584913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels.
    Quizhpe AR; Feres F; de Ribamar Costa J; Abizaid A; Maldonado G; Costa R; Abizaid A; Cano M; Moreira AC; Staico R; Mattos LA; Tanajura LF; Chaves A; Centemero M; Sousa AM; Sousa JE
    Am Heart J; 2007 Aug; 154(2):373-8. PubMed ID: 17643591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous intervention on the saphenous vein bypass grafts--long-term outcomes.
    Bansal D; Muppidi R; Singla S; Sukhija R; Zarich S; Mehta JL; Sachdeva R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):58-61. PubMed ID: 18098183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: Propensity score analysis.
    Applegate RJ; Sacrinty M; Kutcher M; Santos R; Gandhi S; Little W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):7-12. PubMed ID: 18412239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial.
    Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV;
    Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era.
    Pucelikova T; Mehran R; Kirtane AJ; Kim YH; Fahy M; Weisz G; Lansky AJ; Moussa I; Gray WA; Collins MB; Kodali SK; Stone GW; Moses JW; Leon MB; Dangas G
    Am J Cardiol; 2008 Jan; 101(1):63-8. PubMed ID: 18157967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
    J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels.
    Hoffmann R; Hamm C; Nienaber CA; Levenson B; Bonzel T; Sabin G; Senges J; Zahn R; Tebbe U; Pfannebecker T; Richardt HG; Schneider S; Kelm M;
    Coron Artery Dis; 2007 Nov; 18(7):559-64. PubMed ID: 17925610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early beneficial effects of drug-eluting stents in vein grafts wane during long term follow-up: a case-control study.
    Pasceri V; Tarsia G; Niccoli G; Viceconte N; Porto I; Leone AM; Trani C; Speciale G; Lisanti P
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1112-7. PubMed ID: 22422701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
    Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
    J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Procedural success and 10-month outcome between Cypher and TAXUS drug-eluting stents for the treatment of in-stent restenosis].
    Chen JL; Yang YJ; Qiao SB; Yao M; Qin XW; Xu B; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Li JJ; Gao RL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Apr; 35(4):305-7. PubMed ID: 17711652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease.
    Hoye A; Lemos PA; Arampatzis CA; Saia F; Tanabe K; Degertekin M; Hofma S; McFadden E; Sianos G; Smits PC; van der Giessen WJ; de Feyter P; van Domburg RT; Serruys PW
    J Invasive Cardiol; 2004 May; 16(5):230-3. PubMed ID: 15152123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Percutaneous intervention of acutely occluded saphenous vein grafts: contemporary techniques and outcomes.
    Abdel-Karim AR; Banerjee S; Brilakis ES
    J Invasive Cardiol; 2010 Jun; 22(6):253-7. PubMed ID: 20516502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical follow-up of paclitaxel-eluting (TAXUS) stents for the treatment of saphenous vein graft disease.
    Ruchin PE; Faddy SC; Muller DW; Baron DW; Roy PR; Wilson SH
    J Interv Cardiol; 2007 Aug; 20(4):258-64. PubMed ID: 17680855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.